文献速递临床免疫分子诊断质量管理与危急值

高灵敏高特异多重抗体检测定量分析SARS-CoV-2抗原的IgM、IgA和IgG

Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens.
PubMed 文献 · J Clin Microbiol · 2021-01-21

该研究开发了基于xMAP Luminex平台的三种定量悬浮阵列技术(qSAT)检测,针对八种SARS-CoV-2抗原的IgM、IgA和IgG。用128份大流行前血浆和104份SARS-CoV-2确诊者血浆评估性能,最佳抗体/抗原组合特异性100%,症状出现≥14天灵敏度95.78%、≥21天95.65%。

要点

  • qSAT多重抗体检测可定量IgM/IgA/IgG,克服快速检测和ELISA的局限。
  • 最佳组合特异性100%,≥14天灵敏度95.78%,≥21天95.65%。
  • 阴性对照中存在针对N、M、S的预存IgG,提示普通感冒冠状病毒交叉反应。

核心结论

  • 基于xMAP Luminex平台的qSAT多重抗体检测具有高灵敏度和特异性,可准确检测低水平抗体反应。

研究设计与样本

  • 开发三种qSAT检测IgM、IgA、IgG针对八种SARS-CoV-2抗原;用128份大流行前血浆(阴性对照)和104份SARS-CoV-2确诊者血浆(阳性对照,其中5例无症状、51例轻症、48例住院)评估性能。

主要发现

  • 阴性对照中检测到识别N、M、S蛋白的预存IgG抗体,提示对普通感冒冠状病毒的交叉反应。
  • 最佳抗体/抗原组合特异性100%,症状出现≥14天灵敏度95.78%,≥21天灵敏度95.65%,AUC分别为0.977和0.999。

关键数值与推荐

  • 最佳组合特异性100%,≥14天灵敏度95.78%,≥21天灵敏度95.65%,AUC 0.977和0.999。

临床怎么用

  • qSAT多重抗体检测可用于人群SARS-CoV-2暴露流行率调查和免疫相关性研究。

局限性

  • 阴性对照中存在预存IgG抗体,提示与普通感冒冠状病毒交叉反应可能影响特异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Reliable serological tests are required to determine the prevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to characterize immunity to the disease in order to address key knowledge gaps in the coronavirus disease 2019 (COVID-19) pandemic. Quantitative suspension array technology (qSAT) assays based on the xMAP Luminex platform overcome the limitations of rapid diagnostic tests and enzyme-linked immunosorbent assays (ELISAs) with their higher precision, dynamic range, throughput, miniaturization, cost-efficiency, and multiplexing capacity. We developed three qSAT assays for IgM, IgA, and IgG against a panel of eight SARS-CoV-2 antigens, including spike protein (S), nucleocapsid protein (N), and membrane protein (M) constructs. The assays were optimized to minimize the processing time and maximize the signal-to-noise ratio. We evaluated their performances using 128 prepandemic plasma samples (negative controls) and 104 plasma samples from individuals with SARS-CoV-2 diagnosis (positive controls), of whom 5 were asymptomatic, 51 had mild symptoms, and 48 were hospitalized. Preexisting IgG antibodies recognizing N, M, and S proteins were detected in negative controls, which is suggestive of cross-reactivity to common-cold coronaviruses. The best-performing antibody/antigen signatures had specificities of 100% and sensitivities of 95.78% at ≥14 days and 95.65% at ≥21 days since the onset of symptoms, with areas under the curve (AUCs) of 0.977 and 0.999, respectively. Combining multiple markers as assessed by qSAT assays has the highest efficiency, breadth, and versatility to accurately detect low-level antibody responses for obtaining reliable data on the prevalence of exposure to novel pathogens in a population. Our assays will allow gaining insights into antibody correlates of immunity and their kinetics, required for vaccine development to combat the COVID-19 pandemic.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Dobaño C, Vidal M, Santano R, et al. Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens. J Clin Microbiol. 2021. PMID: 33127841. doi:10.1128/JCM.01731-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。